Study: Keytruda reduced the risk of distant metastasis or death versus placebo as adjuvant treatment in melanoma indication

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The phase III EORTC1325/KEYNOTE-054 trial evaluating Keytruda as adjuvant therapy in resected, high-risk stage III melanoma, met the key secondary endpoint of distant metastasis-free survival.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

People of African ancestry (Black/African American) have some of the worst cancer incidence and greatest mortality, compared to white and other racial and ethnic populations in the U.S. On average, Black persons are 1.5 times more likely to have cancer and >2X more likely to die from cancer compared to whites. xxx:more

Login